In a regulatory filing, MiMedx disclosed that its CEO bought 100K shares of common stock on June 22nd in a total transaction size of $640.4K as part of option expiry.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDXG:
- MiMedx price target lowered to $8 from $9.50 at H.C. Wainwright
- MiMedx suspends KOA activity, disbands regenerative medicine business unit
- MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
- MiMedx shares spike 37% after reporting double-digit net sales growth in Q1
- MiMedx price target raised to $9.50 from $8 at H.C. Wainwright